Russo P
Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Curr Treat Options Oncol. 2001 Oct;2(5):447-55. doi: 10.1007/s11864-001-0050-4.
The last decade has brought dramatic changes in our understanding of localized renal tumors. Due to vast improvements in the abdominal imaging modalities of computed tomography (CT), ultrasound, and magnetic resonance imaging (MRI), approximately two-thirds of patients at our center have their renal tumors discovered incidentally. This tumor stage and size migration has vastly improved survival rates; more than 75% of patients with localized renal tumors achieve cure after surgical resection. In addition, the increased presentation of small, incidental tumors has increased the therapeutic options for urologic surgeons with surgical or tumor ablative techniques who now consider preservation of renal function as a goal equally important to local tumor control. Renal cortical tumors, viewed previously as a single type of cancer (ie, hypernephroma, renal cell carcinoma) with a uniform metastatic potential, are far more complex in nature. Renal cortical tumors are a family of neoplasms with distinct histological subtypes and distinct cytogenetic and molecular defects. Metastatic potential, once thought to be dependent only on tumor size, grade, and stage, varies according to tumor histologic subtype, ranging from the most potentially malignant conventional clear cell carcinoma, to the indolent papillary and chromophobe carcinomas, to the virtually benign renal oncocytoma. Surgical approaches to the localized renal cortical tumors now include the classic radical nephrectomy, kidney-sparing surgery, and innovative techniques that involve laparoscopy. New therapeutic modalities, such as renal cryosurgery and radiofrequency ablation, are under active investigation. Whether these new approaches to localized renal tumors will supplement or replace current surgical techniques will depend on the findings of carefully designed and controlled clinical trials.
过去十年间,我们对局限性肾肿瘤的认识发生了巨大变化。由于计算机断层扫描(CT)、超声和磁共振成像(MRI)等腹部成像方式有了极大改进,我们中心约三分之二的患者是偶然发现肾肿瘤的。这种肿瘤分期和大小的变化极大地提高了生存率;超过75%的局限性肾肿瘤患者在手术切除后可治愈。此外,偶然发现的小肿瘤病例增加,为泌尿外科医生提供了更多治疗选择,他们现在将保留肾功能视为与局部肿瘤控制同样重要的目标,可采用手术或肿瘤消融技术。肾皮质肿瘤以前被视为单一类型的癌症(即肾上腺样瘤、肾细胞癌),具有统一的转移潜能,但实际上其性质要复杂得多。肾皮质肿瘤是一组具有不同组织学亚型以及不同细胞遗传学和分子缺陷的肿瘤。转移潜能曾被认为仅取决于肿瘤大小、分级和分期,而现在发现其因肿瘤组织学亚型而异,从最具潜在恶性的传统透明细胞癌,到生长缓慢的乳头状癌和嫌色细胞癌,再到几乎良性的肾嗜酸细胞瘤。目前,针对局限性肾皮质肿瘤的手术方法包括经典的根治性肾切除术、保留肾手术以及涉及腹腔镜检查的创新技术。新的治疗方式,如肾冷冻手术和射频消融,正在积极研究中。这些针对局限性肾肿瘤的新方法能否补充或取代现有的手术技术,将取决于精心设计和控制的临床试验结果。